Crossject SA: Business Overview, Financials & Competitive Analysis
Crossject SA scores 7/10 on the AskCyborg Cyborg Score (Strong). De-risked specialty pharma play with validated needle-free technology platform, strong government backing, and multiple pipeline opportunities in high-value emergency indications. Recent analyst coverage initiated with a 'Strong Buy' recommendation and €4.50 target price. The company has de-risked its lead program with BARDA funding and demonstrated regulatory advancement. However, as a.
What is Crossject SA's industry? Crossject SA (crossject.com) operates in Specialty Pharmaceuticals - Emergency Medicine/Drug Delivery Devices. AskCyborg classifies Crossject SA under Specialty Pharmaceuticals - Emergency Medicine/Drug Delivery Devices in its company registry.
Crossject SA is an emerging specialty pharma company based in France and the U.S. developing ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract with the U.S. Biomedical Advanced Research a...
Cyborg Score thesis
De-risked specialty pharma play with validated needle-free technology platform, strong government backing, and multiple pipeline...
Read the full analyst-debate transcript →Get the Latest Crossject SA Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCrossject SA Overview
Pro stress-test →Crossject SA is an emerging specialty pharma company based in France and the U.S. developing ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The company leverages its proprietary needle-free injection technology to address critical gaps in emergency medicine delivery.
Strategic Profile
Pro stress-test →The company's ZENEO® needle-free autoinjector is designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. Other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks. The company benefits from government validation and multiple regulatory pathways.
Competitive Landscape
Pro stress-test →Crossject operates in the emergency medicine auto-injector market with competitors including EpiPen (Mylan/Pfizer) and emerging needle-free competitors. The company differentiates through proprietary gas-propulsion ZENEO® technology enabling medication delivery through clothing and on bare skin without needles. Government backing and clinical validation provide competitive moats.
Industry Context
Crossject SA operates in Specialty Pharmaceuticals - Emergency Medicine/Drug Delivery Devices.
Key facts
Founded: 2001 · Headquarters: Dijon, France · Market cap: €115.3M